Scientists discover ‘heavenly' new species of poison dart frog in the Amazon
An international team of scientists has announced a newly found species of poison dart frog deep in the Amazon, set apart by its coppery limbs and blue stripes that its discoverers describe as both enchanting and otherworldly.
Found along the banks of the Juruá River in western Brazil, the species joins the Ranitomeya genus of dart frogs, known to be scattered in small populations across the foothills of the Andes Mountains and Amazon rainforest.
The new species is named Ranitomeya aetherea, translated from the Latin word for 'heavenly,' in a decision made by the Brazilian and Czech research team because it 'philosophically refers to the coloration of the species' dorsal stripes: a shade of blue reminiscent of the sky.'
'We attribute this name to one's feeling of enchantment and delicacy when encountering these frogs, as if they were from outside this world,' the research paper announcing the discovery reads.
The frogs were examined for their size, shape and colours, as well as their tadpoles and the 'cricket-like' sounds they made, including 'advertisement' and 'courtship' calls.
After comparing them against the 16 other kinds of Ranitomeya already recognized, researchers describe aetherea as 'readily distinguished' as its own species, notably by its colour pattern.
The aetherea frogs are only the second species of Ranitomeya discovered in a decade. In a study published last month by some of the same researchers, a separate species with a blue-green colouration, Ranitomeya aquamarina, emerged as well.
That name, they wrote, evokes both the colour of seawater and aquamarine gemstones, adding that the latter 'conveys the value of this discovery.'
Jurua river
People move down the Middle Jurua river, Amazonia, Brazil, Friday, Sept. 2, 2022. (AP Photo/Jorge Saenz)
Both frogs were found near the Juruá and its tributaries, a region scientists describe as 'one of the most difficult' in Amazonia, and also one of the least sampled.
To remedy the blind spot, new biodiversity research under the modules of the Rapid Assessment Program for Environmental and Long-Term Ecological Research (RAPELD) has shown 'great improvement,' they say.
While the aetherea have only been observed in a relatively small region thus far, the study notes it may just be a matter of time before more are found.
'The Juruá River area is very poorly studied and it will not be a surprise if future research provides evidence of a wider occurrence of the new species,' the study reads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
a day ago
- National Post
Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
Article content SEATTLE — Pluristyx, a leading provider of tools and services for cell product development, today announced the launch of their first-of-its-kind PluriForm™ Organoid Kit, a turnkey solution to eliminate critical bottlenecks in organoid research and allow scientists to rapidly and reliably make pluripotent aggregates using quality-assured, induced pluripotent stem cells (iPSCs). The kit saves weeks of cell culture work and eliminates variability in organoid manufacturing, allowing reproducible and iterative development and application of organoids. Article content Organoids are three-dimensional cellular models that recapitulate key aspects of organ function. They are used in safety and toxicology screening, drug discovery, disease modeling, and personalized medicine and could replace many instances where animal testing is required. However, organoid use has been hindered by lengthy and highly variable processes to make iPSC aggregates. The PluriForm Organoid Kit solves this challenge by providing a ready-to-use system that includes cryopreserved, Ready-to-Differentiate® (RTD®), suspension-adapted iPSCs and optimized media with a simple protocol. Each kit contains a vial of 25 million cells and all necessary reagents. Within minutes, the end-user can combine the components and generate thousands of uniform aggregates in just one day. These pluripotent aggregates display consistent morphology and size distribution, critical parameters for reproducible differentiation to a wide range of organoids, including neuronal, liver, intestinal, pancreatic, kidney, and cardiac models. Article content 'Our goal is to accelerate the pace of discovery in the pharmaceutical and biotech industries,' said Dr. Benjamin Fryer, Co-founder and CEO of Pluristyx. 'With PluriForm, we have addressed consistent feedback that the initial step of creating reproducible cell aggregates is a major source of delay and inconsistency in organoid workflows.' Article content The FDA's Roadmap to Reduced Animal Testing in Preclinical Safety Studies, released in April 2025, explicitly advocates use of organoids to replace animal models. The PluriForm™ Organoid Kit is essential to enabling and accelerating the transition away from use of animals and other less-than-optimal cell assays and is now available for purchase through Pluristyx direct sales channels. Article content About Pluristyx Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content Article content
CBC
a day ago
- CBC
Squamish fire, Vancouver warning?
The Dryden Creek fire north of Squamish, B.C., is just the latest blaze burning near a city. As wildfires get closer to urban areas across North America, CBC's Johanna Wagstaffe looks at new research that shows cities might actually be making fires worse.
Globe and Mail
2 days ago
- Globe and Mail
Canada should invest in its research talent pipeline, says Canadian Institute For Advanced Research president
Stephen Toope, president of the Canadian Institute For Advanced Research, is a former vice-chancellor of Cambridge University and president of the University of British Columbia. He spoke to The Globe and Mail about the role of CIFAR, which brings people together from a range of disciplines to consider problems on the horizons of research, as a builder of scientific all-star teams. Dr. Toope also discussed the state of research in Canada and the U.S., as President Donald Trump has slashed billions in research funds and attacked several of the most prominent American universities, including Harvard. Q: What do you make of what has been happening between the U.S. government and Harvard? A: It's appalling. And it's not just about Harvard. Billions of dollars of research funding have been removed, arbitrarily, from a whole range of different universities, always for slightly different reasons that don't meet the desires of the U.S. administration. Q: You were invited to Ottawa for the Throne Speech. What are you hearing from the Government of Canada about its plans for research? A: There was a brief mention of research and innovation, rather high level, which was 'to build Canada into the world's leading hub for science and innovation.' That's great. We've also seen the decision to have a minister for artificial intelligence, which suggests a comfort level with trying to deploy new technologies. The proof will be in the pudding. Canada has some catch-up to play here. We have great strengths. We have a lot of solid and sometimes excellent universities. A lot of work needs to be done to make sure that our own ecosystem is strong and supporting research at an adequate level. Q: What does CIFAR do? We create networks of the very top people in the world who are interested in particular subjects. We bring them together across disciplines to try to unlock new approaches, new ideas, that are going to shape the future of research for decades to come. We're focused on some of the hardest questions facing science and humanity in the longer term. We draw the people who are in CIFAR networks from the university world – you might think of them as the all-star team – to work on these really tough questions. Q: How do you do manage an all-star team, and what are the challenges that come with it? The first thing is to conceptualize where we should be expending our resources and what kinds of networks should we bring together. Looking at the horizon and trying to figure out what are the really difficult questions that CIFAR should be looking at now, because they're going to play out importantly in the world over the next 20 to 50 years. That's job one. Job two is talent identification, making sure that we are well connected around the world, so that we know who's doing really exciting work and who has the impulse to work across disciplines collaboratively. Q: Can the world make up for the money being pulled out of U.S. research? No, that's a really important point to make. There's been some talk about how the universities will use some of their endowments, or the foundation world will step up. All of that money is a drop in the bucket, honestly, in relation to what has historically been the U.S. research endeavour. Q: What should Canada be doing in response? What do you think is a wise way to invest? I would start by analyzing where we are before we start inviting lots of new people into the system. Are we actually funding our research at the level that is necessary for a country with an advanced economy? I'm sad to say, I think the answer is no. There was a modest bump up in research funding in the last federal budget of the previous government, but we're still really not operating at the same level of support that many other countries are. We've got to analyze where we should be making core investments to ensure that our whole ecosystem is strong. If we do that, we could then think about some targeted investment to bring in new talent. If I were going to target the investment, I would say early- to mid-career researchers. I wouldn't be going after just two or three big names. Q: Why do you say early-career is better than an established star? Because you've got a longer runway if you can identify truly rising stars, and we've been good at that at CIFAR. If the government could think about a program designed to do that, then you've got people who are more likely to stay. If you invest in a person who's really very far advanced in their career, and then everything switches back with a new government in the U.S., it may be hard to hold on to those people. Q: Tell me about this year's Azrieli scholars, whose names were announced last month? This program is celebrating its 10th anniversary, and it's designed to identify really outstanding young researchers. What we're trying to do is wrap them around with support. So there's financial support to conduct their research, but more importantly there's skills support. How do you set up a lab effectively? How do you manage people? How do you establish priorities and stick with them? We encourage them to be bold, to work across disciplines and to be really ambitious. There are a number of published studies to indicate that despite all of the investment in science, we're actually getting results which are more and more incremental. We want to make sure that the next generation is encouraged to go for the breakthroughs. So we try to identify people from anywhere on the planet, and what they have in common is an aspiration to work across disciplines and a real, bold sensibility. Q: How do you know what a 'bold sensibility' looks like? It's usually around the ambition of the questions they're asking. One of the things CIFAR has been good at historically is pushing people to ask hard questions. Our very first program, 43 years ago, was artificial intelligence, robotics and society. That's pretty darn good in terms of foresight. We're trying to look for people who have that kind of questioning mind. They see an opportunity or challenge that other people haven't noticed yet. This interview has been edited and condensed.
